Ares Capital Corp
F:9A2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ares Capital Corp
F:9A2
|
US |
|
A
|
Alnylam Pharmaceuticals Inc
F:DUL
|
US |
|
C
|
Commerzbank AG
F:CBK
|
DE |
|
B
|
Britania PCL
SET:BRI
|
TH |
|
N
|
Nucor Corp
DUS:NUO
|
US |
|
D
|
DXC Technology Co
F:2XT
|
US |
|
S
|
SBA Communications Corp
XBER:4SB
|
US |
Wall St Price Targets
9A2 Price Targets Summary
Ares Capital Corp
According to Wall Street analysts, the average 1-year price target for 9A2 is 19.309 EUR with a low forecast of 17.299 EUR and a high forecast of 21.77 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 9A2's stock price target?
Price Target
19.309
EUR
According to Wall Street analysts, the average 1-year price target for 9A2 is 19.309 EUR with a low forecast of 17.299 EUR and a high forecast of 21.77 EUR.
What is the Revenue forecast for Ares Capital Corp?
Projected CAGR
1%
Over the last 13 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 1%.
What is the Operating Income forecast for Ares Capital Corp?
Projected CAGR
0%
Over the last 13 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 0%.
What is the Pre-Tax Income forecast for Ares Capital Corp?
Projected CAGR
1%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 8%. The projected CAGR for the next 3 years is 1%.
What is the Net Income forecast for Ares Capital Corp?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Net Income has been 7%. The projected CAGR for the next 3 years is 3%.
